Vimarsana
Biggest News Aggregation in the World

Page 4 - Looking Information News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Information. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Information Today - Breaking & Trending Today

Saturn Oil & Gas Inc. Announces Proposed Private Offering of US$625 million of Senior Secured Second Lien Notes Due 2029 - Vimarsana News

Saturn Oil & Gas Inc. Announces Proposed Private Offering of US$625 million of Senior Secured Second Lien Notes Due 2029

Published: June 4, 2024

Calgary, Alberta--(Newsfile Corp. - June 4, 2024) - Saturn Oil & Gas Inc. (TSX: SOIL) (FSE: SMKA) (OTCQX: OILSF)("Saturn" or the "Company") today announced that, subject to market and other conditions

Source: finanznachrichten.de
Related Topics:
United StatesJohn JeffreyKevin SmithSecurities ExchangeCrescent Point Resources Partnership The AcquisitionAlberta Newsfile CorpVp Corporate DevelopmentVeren PartnershipSaturn Oil Gas Investor Media ContactsSaturn Oil Gas IncFrankfurt Stock ExchangeSecurities ActSouthern SaskatchewanCrescent Point Resources PartnershipGas InvestorMedia ContactsLooking InformationAnnual Information FormSecurities Exchange ActPrivate Securities Litigation Reform ActSaturn OilIhr Portfolio
Christina Lake Cannabis Provides Bi-Weekly Update on Status of MCTO - Vimarsana News

Christina Lake Cannabis Provides Bi-Weekly Update on Status of MCTO

Published: June 3, 2024

VANCOUVER, British Columbia, June 03, 2024 -- Christina Lake Cannabis Corp. is providing an update with respect to the expected timeline for filing its audited financial statements for the fiscal...

Source: marketscreener.com
Related Topics:
Christina LakeBritish ColumbiaUnited KingdomJennifer SmithMark AikenBritish Columbia Securities CommissionCanadian Securities ExchangeChristina Lake Cannabis CorpHealth CanadaLake CannabisRequired DocumentsNational PolicyCease Trade OrdersDefault AnnouncementAnnual FilingsMilan StefancikVice PresidentChief ExecutiveChristina Lake CannabiLooking InformationFiling Deadline
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma - Vimarsana News

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

Published: June 1, 2024

OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Jun 1, 2024--

Source: valdostadailytimes.com
Related Topics:
United StatesJohn CunninghamJun SaitoPeter BorchmannExchange CommissionAmerican Society Of Clinical OncologyInternational MediaUniversity Hospital Of CologneImportant Safety Information European UnionInternational Agency For Research On CancerHealth CanadaEuropean UnionTakeda Pharmaceutical CompanyGerman Hodgkin Study GroupTakeda Pharmaceutical Company LimitedEuropean Hematology AssociationAmerican SocietyClinical OncologyAnnual MeetingUniversity HospitalInternational AgencyEuropean CommissionImportant Safety InformationProduct CharacteristicsHepatic Impairment
Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Vimarsana News

Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Published: June 1, 2024

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median overall survival of...

Source: marketscreener.com
Related Topics:
United StatesSouth KoreaRoger DanseyExchange CommissionAmerican Society Of Clinical OncologyNational Library Of MedicineLeukemia Lymphoma SocietyCollege Of MedicinePfizer IncCatholic University Of KoreaClinical OncologyAnnual MeetingJeunga KimCatholic UniversityChief Development OfficerNorth AmericaDiffuse Largeb Cell LymphomaPrescribing InformationPfizer OncologyBreakthroughs That Change Patient LivesAnnual ReportLooking InformationFactors That May Affect FutureDiffuse Largeb CellUpdated April
Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Region - Vimarsana News

Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Region

Published: June 1, 2024

NEW YORK--(BUSINESS WIRE)--Jun 1, 2024--

Source: eagletribune.com
Related Topics:
United StatesSouth KoreaRoger DanseyCatholic University Of KoreaAmerican Society Of Clinical OncologyNational Library Of MedicineExchange CommissionCollege Of MedicineLeukemia Lymphoma SocietyPfizer IncClinical OncologyAnnual MeetingJeunga KimCatholic UniversityChief Development OfficerNorth AmericaDiffuse Largeb Cell LymphomaPrescribing InformationPfizer OncologyBreakthroughs That Change Patient LivesAnnual ReportLooking InformationFactors That May Affect FutureDiffuse Largeb CellUpdated April